Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

Aaron Boster; Mary Pat Bartoszek; Colleen O'connell; David Pitt; Michael Racke

doi:10.1177/1756285611422108

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

Aaron Boster, Mary Pat Bartoszek, Colleen O'connell, David Pitt, Michael Racke

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

40 Citas (Scopus)

Resumen

The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.

Idioma original	English
Páginas (desde-hasta)	319-332
Número de páginas	14
Publicación	Therapeutic Advances in Neurological Disorders
Volumen	4
N.º	5
DOI	https://doi.org/10.1177/1756285611422108
Estado	Published - sep. 2011
Publicado de forma externa	Sí

Nota bibliográfica

Funding Information:
This work was supported by NINDS (grant number RO1 NS 037513 to MKR).

ASJC Scopus Subject Areas

Pharmacology
Neurology
Clinical Neurology

Acceder al documento

10.1177/1756285611422108

Otros archivos y enlaces

Citar esto

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. / Boster, Aaron; Bartoszek, Mary Pat; O'connell, Colleen et al.
En: Therapeutic Advances in Neurological Disorders, Vol. 4, N.º 5, 09.2011, p. 319-332.

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

@article{7ee63df992e849b4985a0d168c0241fd,

title = "Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis",

abstract = "The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.",

author = "Aaron Boster and Bartoszek, {Mary Pat} and Colleen O'connell and David Pitt and Michael Racke",

note = "Funding Information: This work was supported by NINDS (grant number RO1 NS 037513 to MKR). ",

year = "2011",

month = sep,

doi = "10.1177/1756285611422108",

language = "English",

volume = "4",

pages = "319--332",

journal = "Therapeutic Advances in Neurological Disorders",

issn = "1756-2856",

publisher = "SAGE Publications Ltd",

number = "5",

}

TY - JOUR

T1 - Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

AU - Boster, Aaron

AU - Bartoszek, Mary Pat

AU - O'connell, Colleen

AU - Pitt, David

AU - Racke, Michael

N1 - Funding Information: This work was supported by NINDS (grant number RO1 NS 037513 to MKR).

PY - 2011/9

Y1 - 2011/9

N2 - The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.

AB - The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.

UR - http://www.scopus.com/inward/record.url?scp=80053327895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053327895&partnerID=8YFLogxK

U2 - 10.1177/1756285611422108

DO - 10.1177/1756285611422108

M3 - Review article

AN - SCOPUS:80053327895

SN - 1756-2856

VL - 4

SP - 319

EP - 332

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

IS - 5

ER -

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto